A phase II study designed to evaluate the safety, tolerability, and effect of a single, rising dose of intravenous AL-208, followed by a placebo-controlled, double-blind, parallel-group evaluation of a single dose of AL-208, on mild cognitive impairment following coronary artery bypass graft surgery

Trial Profile

A phase II study designed to evaluate the safety, tolerability, and effect of a single, rising dose of intravenous AL-208, followed by a placebo-controlled, double-blind, parallel-group evaluation of a single dose of AL-208, on mild cognitive impairment following coronary artery bypass graft surgery

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2012

At a glance

  • Drugs Davunetide (Primary)
  • Indications Mild cognitive impairment
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Sep 2008 Planned end date changed from 1 Mar 2008 to 1 Mar 2008.
    • 11 Sep 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Aug 2008 Top-line results expected in third quater 2008 according to Allon Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top